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Abstract 
 
Determination of the chiral composition of drugs is nowadays a key step in order to determine 
purity, activity, bioavailability, biodegradation, etc, of pharmaceuticals. In this manuscript, works 
published for the last 5 years on the analysis of chiral drugs by liquid separation techniques coupled 
with mass spectrometry are reviewed. Namely, chiral analysis of pharmaceuticals including e.g., 
antiinflammatories, antihypertensives, relaxants, etc, by liquid chromatography-mass spectrometry 
and capillary electrophoresis-mass spectrometry are included. The importance and interest of the 
analysis of the enantiomers of the active compound and its metabolites in different biological fluids 
(plasma, urine, cerebrospinal fluid, etc) are also discussed.  
 
Keywords: LC-MS; CE-MS; Enantiomers; Drugs; Capillary electrophoresis; Biological fluids; 
Hyphenated techniques; Liquid chromatography; Metabolites; Sample preparation; CEC-MS. 
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1. Introduction 
 
In the past thirty years, there has been a growing interest in the pharmaceutical industry and 
analytical laboratories for the analysis and quantification of the enantiomers of chiral drugs, being 
this chiral analysis nowadays required by pharmaceutical regulatory authorities. This is basically 
due to the different therapeutic effects that two enantiomers can have. Whereas one can have 
beneficial applications, the other can have none or even adverse effects.  
 
Numerous analytical techniques have been developed to respond to this requirement and among 
them, liquid separation techniques such as liquid chromatography (LC) and capillary 
electrophoresis (CE) have been demonstrated to play an important role [1]. 
 
Recently a new step has been taken with the detection of chiral compounds in biological fluids [2], 
a topic of paramount importance for the pharmaceutical industry. The key application is the 
possibility e.g., to determine in-vivo the pharmacokinetic properties of a drug, including absorption, 
distribution, metabolism and excretion (ADME) [3]. This allows a better understanding of the 
action of chiral drugs and their metabolites, to determine which enantiomer is the most efficient in a 
racemic mixture, and so, propose a better and/or safer treatment based on a single enantiomer. 
Other applications include studies of chiral inversion in-vivo and detection of chiral biomarkers [4]. 
In comparison to the analysis of chiral drugs directly dissolved in a solvent, their analysis in 
biological samples can be extremely problematic. Biological fluids (i.e. urine, plasma, etc) are 
extremely complex matrices and contain low-molecular mass compounds, salts and proteins. Some 
of those can be at high concentration. Different problems can be expected; first of all the 
chromatograms (or electropherograms) can become extremely complex, and co-elution (or co-
migration) become frequent and difficult to detect. Secondly, analytes in those matrices can form 
complexes especially with metal ions, and thus their analysis time can be shifted, which may lead 
to false negatives without a proper analytical tool. Moreover, the pharmaceutical of interest and its 
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metabolites will frequently have to be accurately measure at very low concentrations. Therefore, to 
obtain the required robustness and sensitivity in a reasonable time, all steps of the analytical 
method should be optimized. Those steps include the sample preparation, the chiral separation and 
the detection.  
 
The sample preparation is an important step, as it will allow simplification of the matrix. This step 
includes e.g., proteins removing, desalting, liquid-liquid extraction (LLE) or solid phase extraction 
(SPE) [5,6]. Sample pretreatments are generally time consuming and as a result it is often assumed 
that the sample preparation is the longest step in the whole analytical method. As mentioned above, 
among the liquid separation techniques developed to achieve the chiral separation of drugs, liquid 
chromatography (LC) and capillary electrophoresis (CE) have been demonstrated to play an 
important role [1] themselves or hyphenated to mass spectrometry (MS) techniques. One of the 
major breakthroughs for the determination of chiral analytes in biological matrix has been the 
development of new MS interfaces, especially the development of atmospheric pressure ionization 
(API) sources such as electrospray ionization (ESI) and atmospheric pressure chemical ionization 
(APCI) that simplified the compatibility between the separation step working in the liquid phase 
and the mass spectrometer detector working in the gas phase.  
 
MS allows an unambiguous assignment of the different chromatographic or electrophoretic peaks. 
For instance, comparisons of the mass spectra of the main peaks with their corresponding standard 
spectra allows knowing without ambiguity their identity and if there is e.g., co-elution. The full 
mass spectra and MS/MS spectra can also give information about the structure of the metabolites. 
MS/MS allows selection of one specific ion/fragment, this permits obtaining a very clean 
chromatogram where, with a careful selection, the only peaks will be the ones of the analytes of 
interest.  
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It was believed that the development of MS, MS/MS and MSn would permit a direct analysis 
without the need of a separation and/or sample pre-treatment. However, it has been demonstrated to 
be unrealistic and more in the case of chiral analysis, where both enantiomers will have the same 
mass spectra and, therefore, baseline separation will have to be obtained before the MS detector. 
Moreover, presence of co-migrating species can reduce the MS signal and give errors on the 
measure (matrix effect) [7]. Also, non-volatile components will accumulate at the ion-source 
reducing the signal too. Therefore, it is clear that although MS detection allows simplification of 
the pre-treatment and separations steps, they are still very important steps of any method 
development.  
 
2. Scope 
 
This review will cover the papers published from 2000 to April 2005 on liquid separation 
techniques coupled with mass spectrometry for chiral analysis of pharmaceuticals compounds and 
their metabolites in biological fluids. The liquid separation techniques reviewed will include liquid 
chromatography (LC), capillary electrophoresis (CE) and capillary electrochromatography (CEC). 
This review will be separated in two main parts. The first one will be focus on the pre-treatment 
step, and the second part on the separation and detection step. The papers based on liquid 
chromatography separation techniques are summarized in Table 1, including other useful data as 
pharmaceutical analyzed, type of column and mobile phase used, sample preparation applied, API 
interface, matrix and limit of quantification (LOQ) achieved. The one related to capillary 
electrophoresis and electrochromatography are summarized in Table 2, providing in this case 
information on the pharmaceutical analyzed, type of capillary, background electrolyte (BGE), 
sample preparation applied, API interface used, the matrix analyzed and LOQ achieved. 
 
3. Sample preparation. 
3.1. Plasma and serum sample. 
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For the analysis of plasma and serum samples, direct injection into the separation instrument is 
usually avoided, as their high proteins content will clog the column or capillary. Although protein 
precipitation is usually the first step of the sample preparation procedure, in some applications 
where sensitivity and robustness are not so important it can be the only step. For instance, Rashed 
et al [46] used only protein precipitation as sample clean-up to analyze L-pipecolic acid, an 
important biochemical marker for the diagnosis of peroxisomal disorders, in human plasma. 
Although relatively high limits of quantification (LOQ) were found using this procedure [46], the 
LOQ was still five times higher than the average concentration found in human plasma from 
healthy volunteers. Similarly, carvidol [20] and gemifloxacin [24] enantiomers have been 
successfully analyzed after a simple protein precipitation. In the case of gemifloxacin [24], a new 
antibiotic, Ramji et al. monitor both enantiomers and their metabolites after oral and intravenous 
injection in rat and dogs. But whereas a chiral LC-MS method, with a simple protein precipitation 
was used for the analysis of the enantiomers, the analysis of metabolites required a solid phase 
extraction (SPE) treatment of the samples. SPE is the most widely used sample clean up techniques. 
This is probably due to its relative simplicity, its large range of application and the possibility to 
use semi-automated apparatus (96 well plate and robotized arm, for example) or to develop on-line 
coupling approaches [8]. The method consists of four steps: conditioning, sample load, washing 
step and elution. More information about sample clean-up in electromigration, chromatographic 
and mass spectrometric separation methods can be found in the review by Gilar and co-workers [9].  
 
Eichold and co-worker [28] used LC-MS following an automated SPE procedure with a 96-well 
plate to measure the ketoprofen enantiomeric concentration in human plasma. Ketoprofen is an 
anti-inflammatory marketed as a racemic mixture. However, it is accepted that the (S) form is the 
one active, and it is therefore desirable to perform enantioselective concentration measurements in 
plasma. The combination of chiral LC-MS and semi automated SPE allows them to obtain a very 
low LOQ with a relatively high throughput. Thus, they were able to monitor the concentration of 
both enantiomers in plasma following oral and topical administration. Another popular set-up is 
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online-SPE either in a single column or column-switching (CS) configurations (see Figure 1). In the 
first step the sample is injected into the SPE column, where analytes of interest are retained and 
matrix components are washed out. The chiral column is usually conditioned in the same time with 
the mobile phase. Then the SPE column is connected to the chiral column, and analytes are eluted. 
Wu et al. [13] used a similar set-up to analyze albuterol enantiomers, a drug used to help asthma 
patients, in dog plasma. They design a high throughput method with a sample turnout of 8 minutes. 
Xia and co-workers [47,49] used an on-line dual column switching approach in conjunction with 
chiral LC-MS. This allows them to use a SPE column coupled on-line with the chiral column for 
the extraction/separation while the other column was equilibrated. In this way a significant 
increasing of sample throughput was achieved without sacrificing sensitivity or precision. They 
validate their approach by quantifying propranolol enantiomers in rat plasma [47] and terbutaline 
enantiomers in human plasma [49].  Other examples of on-line-SPE-LC-MS can be found in Table 
1. 
 
Liquid-liquid extraction (LLE) is an alternative to SPE when more robust and sensitive LC-MS 
methods are needed. LLE is considered more time and resources consuming than SPE but can 
potentially (depending on the choice of solvent) provides cleaner extracts. Use of liquid-handling 
workstation permits to work in semi-automated way. This approach has been used by Bakhtiar et al 
[34-39] to develop a chiral LC-MS method for the quantification of methylphenidate enantiomers, a 
drug prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) and 
narcolepsy, in plasma. They applied this method to numerous toxycokinetic studies.  
 
Although SPE and LLE are the main techniques used for sample clean-up other approaches exist. 
Goda et al [18] use an ultrafiltration membrane and ultra-centrifugation to clean-up plasma and 
cerebrospinal fluid (CSP) samples. Their results showed that no matrix effects and no co-eluting 
peaks interfere with the enantiomeric quantification of baclofen, a muscle relaxant. Motoyama and 
colleagues [45] used a simple centrifugation and filtration step before injecting the serum sample 
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onto a pre-column with a strong cation exchange stationary phase. The purified eluent was then 
injected to the chiral column using a column-switching system. They applied this approach to the 
enantiomeric determination of pindolol in human serum, and obtain a low LOQ and a good intra- 
and inter-day reproducibility.  
 
3.2 Urine and other biological matrices. 
 
Urine is a matrix usually devoid of proteins and, although SPE and LLE are still the two preferred 
sample clean-up method for sensitive applications, when a high throughput is preferable a simple 
filtration might be sufficient. This has already been demonstrated by Rashed et al. [12,25] with the 
analysis of the enantiomers of 2-hydroxyglutaric acid [12] and glyceric acid [25]. Each of these 
enantiomers is a specific biomarker of an inherited metabolic disease (D-2-Hydroxyglutaric 
aciduria, L-2-hydroxyglutaric aciduria, D-glyceric aciduria and L-glyceric aciduria respectively). 
To obtain a simple chromatogram, they develop a MS-MS method using multiple reactions 
monitoring mode (MRM). They were able to diagnosis the disease with this simple sample clean-up 
(i.e., filtration). 
 
4. Separation and detection 
4.1. Liquid chromatography 
 
Liquid chromatography (LC) is one of the main separation techniques in liquid phase. Chiral 
separation can be achieved in two ways, either using a chiral reagent, or using a chiral stationary 
phase (CSP). Due to the extra time required for the chiral derivatization and the wide choice of CSP 
column available in the market, the uses of chiral reagents tend to disappear. Yang et al. [20] used 
2,3,4,6-tetra-O-acetyl-beta-d-glucopyranosyl isothiocyanate (GITC) as a chiral reagent to separate 
and quantify enantiomers of carvedilol in human plasma. The separation was performed on an Ace 
3 C18 column and the eluent was transferred to the MS using an atmospheric pressure chemical 
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ionization (APCI) source. Carvedilol is an anti-hypertensive agent that has been used in treatment 
of congestive heart failure. In order to determine the stereospecificity exhibited in the metabolism 
and disposition of carvedilol, an analytical method for the quantitative analysis of each enantiomer 
was required. On the other hand, Zoutendam et al. [44] used (−)-1-(9-fluorenyl)ethyl chloroformate 
(FLEC) as a chiral reagent to develop an analytical technique that will be used for the enantiomeric 
pharmacokinetics studies of the enantiomers in plasma. The column used was in this case a C18, 
and the MS was interfaced using an electrospray ionization (ESI) source. 
 
Table 1 shows that various CSPs have been successfully used for pharmacokinetic studies. The 
choice of the mobile phase is determined among other factors by the MS interface. In general the 
atmospheric pressure chemical ionization (APCI) source is not suitable with flammable solvent 
and, therefore, it is difficult to apply together with normal phase chiral chromatography. For 
instance, tramadol, MK-0767 and a chiral sulfoxide drug candidate were separated by normal phase 
with an APCI source. Miller-Stein and Fernandez-Metzler [22] mixed the eluent at the output of the 
column with an aqueous solution before the APCI source to allow the enantiomeric 
pharmacokinetic and metabolic characterizations of a sulfoxide drug candidate using normal phase 
chiral LC-MS. A similar approach has been used by Yan et al. [41]. Ceccato et al. [50] analyzed 
both enantiomers of tramadol and its metabolites by setting the probe at a low temperature. 
Similarly, when using an electrospray ionization (ESI) source with flammable solvents some risk 
can exist. To overcome this risk, Jabor et al. [29, 30] used a make-up flow that was mixed with the 
eluent. The mixed flow was then split before being transferred to the MS source. Using this 
approach they develop a new method to quantify enantiomers of lercanidipine, a drug used for the 
treatment of hypertension, in human plasma [29]. They applied this method to the enantioselective 
pharmacokinetics of lercanidipine in healthy volunteers, and show that the pharmacokinetics was 
enantioselective following a single dose of the racemic drug. 
 
4.2. Capillary electrophoresis  
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Capillary electrophoresis is a growing analytical technique with numerous advantages. It exhibits 
much higher efficiency and faster migration time than LC and need lower volume of samples (few 
nanoliters). Moreover, since the chiral selectors are mixed with the background electrolyte (BGE), 
it is easy to try numerous chiral selectors at different concentrations. The volume in the column is 
also very low what makes affordable to try expensive chiral selectors. Blocking is less likely to 
occur in CE-MS as the column is open, thus can allow a simplified sample clean-up procedure. The 
main disadvantage is the relatively poor limit of detection. CE and LC are complementary 
techniques. Whether for application needing a very low LOQ, LC can be the method of choice, for 
fast and efficient applications CE can provide a very interesting alternative. Heinemann [17] 
compared the separation of azelastine and three of its metabolites by CE and HPLC. As it can be 
seen in Figure 2, the advantage in term of speed, efficiency and chiral separation using CE is 
striking. However, in that work [17] only the LC method was interfaced to MS and, therefore, 
limits of quantification could not be compared between the two methods (HPLC-MS vs. CE-MS).  
 
ESI is the interface most frequently applied for CE-MS coupling and, as a consequence, it is 
important to insure that only volatile components enter the ESI-MS interface. Different approaches 
have been used to avoid that the chiral selector enter the source as for instance the partial filling 
technique, the use of charged chiral selector which will migrate away from the MS or the employ of 
counter-current modes [10]. Toussaint et al. [52] used neutral dimethyl-β-cyclodextrin in acidic 
conditions with a partial filling technique to separate clenbuterol enantiomers, a drug used in the 
treatment in the treatment of pulmonary diseases, in human plasma. Clenbuterol was used as a test 
chiral analyte to show that CE-MS can be applied to the determination of chiral drugs in complex 
mixtures.The influence of the BGE composition on the sensitivity of MS detection was also 
investigated. Rudaz and co-workers [55] used charged cyclodextrin and a polyviniyl coated 
capillary for the stereoselective analysis of tramadol, and analgesic formulated as a racemic mixture 
and its main metabolites in plasma sample. They succeed in separating and detecting both 
enantiomers and metabolites in a plasma sample collected from a healthy volunteer 2 h after oral 
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administration of 100 mg of tramadol hydrochloride. Kindt et al. [53] developed a partial filling 
CE-MS approach to quantify the enantiomers of a novel drug in plasma, and to determine its 
potential for chiral interconversion. Using a similar approach, Cherkaoui and colleagues [54] 
separated enantiomers of methadone in human serum.  
 
4.3. Capillary electrochromatography (CEC). 
 
Capillary electrochromatography can be defined as an analytical procedure in which LC and CE are 
put together. In CEC the separation is achieved in a packed column, but the transport is due to the 
electroosmotic flow induced by the electric field. This allows a similar separation process as in LC 
with a significant increase in efficiency. Zheng and Shamsi [56] designed a CEC-ESI-MS method 
to quantify the enantiomers of warfarin, an oral anticoagulant, in human plasma. Both enantiomers 
exhibit marked differences in their pharmacokinetics and pharmacodynamics properties. In 
addition, the importance of monitoring the concentration ratio of (±)-warfarin in patients with 
thromboembolic disease was demonstrated. CEC capillaries packed with (3R,4S)-Whelk-O1 chiral 
stationary phase were used for simultaneous enantioseparation of warfarin and its internal standard 
coumachlor. They investigated the influence of the column fabrication, as well as the influence of 
the composition of the mobile phase. The method was applied to the analysis of human plasma 
spiked with warfarin enantiomers (see Figure 3). 
 
5. Conclusions and perspectives. 
 
It is clear that nowadays the use of LC-MS for chiral separation of drugs and metabolites is more 
widely used than CE-MS techniques (compare Table 1 and Table 2). However, the important 
advantages that CE and CEC techniques can provide (e.g., faster, more efficient and cheaper 
analysis) make foreseeable that these techniques coupled with MS become more and more widely 
applied. Moreover, the high throughput shown by using microchips together with different 
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detectors for chiral separations [57-63], could be corroborated in the non-distant future by using 
microchip-MS couplings [64-65] for chiral analysis of drugs and their metabolites in complex 
matrices. 
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Table 1. Chiral separation in biological matrix by LC-MS. NR indicates that the result or condition was not reported. 
 
Pharmaceutical Column Mobile phase Sample 
preparation 
API 
interface 
matrix Ref LOQ 
12-HETE chiral CD-ph methanol:water:acetic acid 
(65:35:0.02) 
SPE  ESI Urine [11] NR 
2-hydroxyglutaric 
acid 
Chirobiotic R triethylammonium acetate (pH 
7):methanol (9:1) 
Filtration  ESI Urine [12] NR 
Albuterol Chirobiotic T methanol, 0.02% formic acid, 
0.1% ammonium formate 
SPE ESI Plasma [13] NR 
Albuterol Chitobiotic T methanol:Acetic acid:ammonium 
(1000:5:1) 
SPE  APCI Plasma [14] 0.25 ng/ml 
Amlodipine Chiral AGP ammonium acetate (10mM 
pH4.5):1-propanol (99:1) 
SPE  APCI Plasma [15] 0.1 ng/ml 
Anticholinergic 
analogs 
Cyclobond I 2000 
ß-CD 
acetonitrile: methanol: acetic acid: 
TEA (95:5:0.5:0.3) 
SPE ESI Serum [16] 1 ng/ml 
Azelastine Chiralpak AD ammonium 
acetate:ACN:methanol 
(80:12:8) 
LLE  ESI Plasma [17] 40 ng/ml 
Baclofen Crownpak CR ammonium acetate:methanol (9:1) ultra -
centrifugation 
APCI Plasma,  
CSF 
[18] 0.15 ng/ml 
Buvicaine ChromTeck AGP 3% n-propanol in water + 5 mM 
ammonium acetate 
LLE  ESI Urine [19] NR 
Carvedilol C18 (GITC as 
chiral reagent) 
water:CAN (50:50) protein 
precipitation  
ESI Plasma [20] 0.2 ng/ml 
CGS 26214 Chiral AGP 3% n-propanol, 0.03% ammonium 
acetate in water 
SPE ESI Plasma [21] 0.4 ng/ml 
chiral sulfoxide 
drug candidate 
Chiralpak-AD 2-propanol:iso-hexane 
(80:20) 
SPE APCI Plasma [22] 5 ng/ml 
Felodipine Chiralcel OJ-R 2 propanol:iso-hexane 
(11:89) 
LLE  ESI Plasma [23] 0.1 ng/ml 
Gemifloxacin Crownpak CR NR Protein 
precipitation 
ESI Plasma [24] 10 ng/ml 
Glyceric acid Chirobiotic 0.1% triethylammonium acetate 
(pH 4.1): methanol (9:1) 
NR ESI Urine [25] NR 
Ibuprofen Chiralpak-AD-RH methanol:water +0.1% Phosphoric 
acid (8:2 v/v) 
LLE  ESI Plasma [26] 0.12 μg/ml 
Ketamine Chiral AGP propanol:ammonium acetate 
(10mM, pH7.6) (6:94) 
SPE ESI Plasma [27] 1 ng/ml 
Ketoprofen Chirex 3005 ammonium acetate (30 mM, pH 
3.5):methanol (5:96) 
SPE  ESI Plasma [28] 0.05 ng/ml 
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Lercanidipine Chiralpak AD hexane:ethanol:diethylamine 
(95:5:01) 
LLE  ESI Plasma [29, 30] 25 ng/ml 
Methadone Chiral AGP ammonium formate:methanol  SPE  ESI Plasma [31] 0.1 ng/ml 
Methadone Chiral AGP ACN:ammonium acetate buffer 
(10mM pH 7.0) 
centrifugation ESI Saliva [32] 5 ng/ml 
Methadone Chiral AGP isopropyl:ammonium acetate (10 
mM, pH unadjusted) (12:88) 
LLE  ESI Plasma [33] 5 ng/ml 
Methylphenidate Chirobiotic V methanol + 0.05 % ammonium 
TFA 
LLE  APCI Fetal 
tissues 
[34] 0.218 ng/g 
Methylphenidate Chirobiotic V methanol + 0.05 % ammonium 
TFA 
LLE  APCI Plasma [35-39] 1 ng/ml 
Metrifonate ChiralPak AS Ethanol with 1% water:n-heptane 
(25:75) 
LLE ESI Blood, 
brain 
tissues 
[40] 5 ng/ml 
7.5 ng/g 
MK-0767 Kromasil CHI-
DMB 
hexane:isopropanol (+0.1% 
formic acid) (81:19) 
LLE  APCI Plasma [41] 1 ng/ml 
Nefopam Chirobiotic V  methanol + 0.1% ammonium TFA LLE  ESI Plasma, 
urine 
[42] 0.9 ng/ml 
Omeprazole Chiralpak AD-RH ACN:ammonium acetate (50 mM, 
pH 4.65) (36:65) 
SPE  ESI Plasma [43] N/A 
PGE-9509924 C18 (FLEC as 
derivatizing agent) 
methanol:ACN:water:formic acid 
(40:40:20:0.1) 
SPE  APCI Plasma [44] 25 ng/ml 
Pindolol Chiral DRUG  
(ß-CD) 
Ammonium acetate (10mM):ACN 
(50:50)  
cation 
exchange 
ESI Serum, 
urine 
[45] 0.13 ng/ml 
Pipecolic acid Chirobiotic T methanol:water (60:40) protein 
precipitation 
ESI Plasma [46] 30 ng/ml 
Propanolol Chirobiotic T Methanol, 0.035% ammonium 
TFA 
SPE  APCI Plasma [47] 2 ng/ml 
TaClo Chiralcel OD-R Water:ACN (60:40), 0.1% TFA SPE  ESI Blood 
clots 
[48] 50 pg/g 
Terbutaline Chirobiotic T methanol, 0.1% ammonium TFA 
 
SPE APCI Plasma [49] 1 ng/ml 
Tramadol Chiralpak AD isohexane:ethanol: diethylamine 
(97:3:0.1) 
SPE APCI Plasma [50] 0.5 ng/ml 
Verpomil Chiral AGP ACN:ammonium acetate (20 mM, 
pH 7.4) (15:85) 
LLE  ESI Plasma [51] 0.1 ng/ml 
 
 16 
Table 2. Chiral separation in biological matrix by CE-MS and CEC-MS. NR indicates that the result or condition was not reported. 
 
 
Pharmaceutical capillary BGE Sample 
preparation 
API 
interface 
matrix Ref LOQ 
Clenbuterol CE, no coating Ammonium acetate buffer (10 mM 
pH2.5):methanol (80:20) + 40 mM 
DM-ß-CD 
SPE ESI Plasma [52] 490 ng/ml 
PD0217015 and 
PD0217016 
CE, no coating ACN: ammonium acetate buffer 
(5mM): acetic acid: HS-ß-
cyclodextrin (25:75:1:0.3) 
LLE ESI Plasma [53] 10 ng/ml 
Methadone CE, polyvinyl alcohol 
coated 
Ammonium acetate (40 mM, pH 4) 
+ 1mg/ml CM-ß-CD 
LLE ESI Serum [54] NR 
Tramadol CE, polyvinyl alcohol 
coated 
Ammonium acetate buffer (40 mM 
pH4) + 2.5 mg/ml SBE-ß-CD 
LLE ESI Plasma [55] NR 
Warfarin CEC, packed w ith 
(3R,4S)-Whelk-O1 
Ammonium acetate buffer (5 mM 
pH 4.0):ACN (30:71) 
SPE ESI Plasma [56] 25 ng/ml 
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FIGURE LEGENDS 
 
 
Figure 1.  On-line SPE with column switching configuration. 
 
 
Figure 2.   A HPLC separation of the enantiomers of azelastine (AZ) and its metabolites on a 
Chiralpak AD column (25034.6 mm, 10 mm material) with a flow-rate of 1.2 ml/min 
and UV detection at 235 nm with n-hexane–ethanol–diethylamine (97:3:0.7, v/v). B. 
Chiral CE separation of the standard mixture in an uncoated fused-silica capillary 
using UV detection at 214 nm. Buffer: H3PO4 100 mM, pH 5.25 with 
triethanolamine, 3% methanol, 14 mg/ml CM-β-CD and 16 mg/ml β-CD. Field 
strength: 1426 V/cm. Redrawn from Heinemann et al. [17]. 
 
Figure 3.   Analysis of human plasma spiked with 0.1 μg/ml (R)-warfarin and 10.0 μg/ml (S)-
warfarin. The inset shows the expanded version of enantiomeric peaks. Conditions: 
mobile phase, ACN/H2O (70:30, v/v) containing 5 mM NH4OAc, pH 4.0; injection, 
12 bar for 3 min; sheath liquid, 70% (v/v) CH3OH containing 5 mM NH4OAc (pH 
8.5), flow rate 7.5 μL/min. MS spray chamber parameters: drying gas flow rate 5 
L/min; drying gas temperature, 350 °C; nebulizer pressure, 0.276 bar (4 psi); 
capillary voltage, -2500 V; fragmentor voltage, 91 V. Redrawn from Zheng and 
Shamsi [56]. 
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